[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5547 Introduced in House (IH)]

<DOC>






118th CONGRESS
  1st Session
                                H. R. 5547

   To amend title XI of the Social Security Act to protect access to 
                   genetically targeted technologies.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                           September 18, 2023

 Mr. Nickel (for himself, Mr. Joyce of Pennsylvania, and Mr. Davis of 
 North Carolina) introduced the following bill; which was referred to 
the Committee on Energy and Commerce, and in addition to the Committee 
 on Ways and Means, for a period to be subsequently determined by the 
  Speaker, in each case for consideration of such provisions as fall 
           within the jurisdiction of the committee concerned

_______________________________________________________________________

                                 A BILL


 
   To amend title XI of the Social Security Act to protect access to 
                   genetically targeted technologies.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Maintaining Investments in New 
Innovation Act''.

SEC. 2. AMENDMENT TO DEFINITION OF QUALIFYING SINGLE SOURCE DRUG.

    Section 1192(e) of the Social Security Act (42 U.S.C. 1320f-1(e)) 
is amended--
            (1) in paragraph (1)(A)(ii), by inserting ``(or, in the 
        case of an advanced drug product (as defined in paragraph (4)), 
        11 years)'' after ``7 years''; and
            (2) by adding at the end the following new paragraph:
            ``(4) Advanced drug product defined.--For purposes of 
        paragraph (1)(A)(ii), the term `advanced drug product' means a 
        drug that incorporates or utilizes a genetically targeted 
        technology (as defined in section 529A(c)(2) of the Federal 
        Food, Drug, and Cosmetic Act) that may result in the modulation 
        (including suppression, up-regulation, or activation) of the 
        function of a gene or its associated gene product.''.
                                 <all>